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Abstract
Background: Although gastrointestinal endoscopy with sedation is increasingly performed in elderly patients, data
on combined sedation with midazolam/propofol are very limited for this age group.
Methods: We retrospectively analyzed 454 endoscopic procedures in 347 hospitalized patients ≥ 70 years who had
received combined sedation with midazolam/propofol. 513 endoscopic procedures in 397 hospitalized patients <
70 years during the observation period served as controls. Characteristics of endoscopic procedures, co-morbidity,
complications and mortality were compared.
Results: Elderly patients had a higher level of co-morbidity and needed lower mean propofol doses for sedation.
We observed no major complication and no difference in the number of minor complications. The procedure-
associated mortality was 0%; the 28-day mortality was significantly higher in the elderly (2.9% vs. 1.0%).
Conclusions: In this study on elderly patients with high level co-morbidity, a favourable safety profile was
observed for a combined sedation with midazolam/propofol with a higher sensitivity to propofol in the elderly.
Background
Sedation for endoscopic procedures ideally results in
relief of patient discomfort and anxiety while improving
the outcome of endoscopic procedure, in particular
when performing interventional endoscopic procedures.
A recent meta-analysis concluded that moderate seda-
tion increases both patient and physician satisfaction [1].
While sedation for gastrointestinal endoscopy tradition-
ally has been achieved with benzodiazepines (e.g. mida-
zolam [2]) propofol (2, 6 diisopropyl phenol), an ultra
short-acting hypnotic agent, has emerged as a possibly
superior alternative [3,4]. Thus, propofol simplified the
technical performance of colonoscopy [5] and increased
the quality of upper endoscopy in comparison to mida-
zolam [6]. Propofol sedation also has the advantage of a
s h o r t e n e dr e c o v e r yt i m e[ 1 , 7 ] .T h e r ea r eh o w e v e rw e l l -
known disadvantages of propofol, in particular the dose-
dependent potential to induce general anaesthesia or
hemodynamic and respiratory depression, and the lack
of a pharmacologic antagonist [8]. However, data from a
recent meta-analysis suggest that propofol sedation is
n o ta s s o c i a t e dw i t ha ni n c r e a s ed risk for complications.
On the contrary, propofol sedation for colonoscopy was
associated with lower complication rates than sedation
with traditional agents [9]. Although the side-effects of
propofol are particularly worrisome in the geriatric
population, the limited data available suggest that pro-
pofol can be used with a favourable safety profile in
e l d e r l yp a t i e n t sa sl o n ga ss m a l l e rd o s e sa n ds l o w e r
application rates are used [10-12].
The combination of propofol and midazolam has
synergistic effects [13,14] and may have advantages over
the use of propofol as a single agent. Thus, a combined
sedation regimen with a benzodiazepine retains the pos-
sibility for partial pharmacologic reversibility using flu-
mazenil. Moreover, the propofol dose can be
significantly reduced and a more precise dose-titration
with smaller bolus doses becomes possible. This was
s h o w ni na no b s e r v a t i o n a ls t u d yo nm o r et h a n2 0 0
patients, where 59% reduction of the propofol dose was
possible using midazolam induction followed by propo-
fol titration for interventional endoscopy. Significant
complications were not observed [15]. This finding was
confirmed in several prospective studies where lower
doses were needed for combined sedation with midazo-
lam/propofol compared to single agent propofol during
diagnostic or therapeutic endoscopy [16-19].
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hemodynamic and respiratory depression or irreversible
oversedation could be minimized and a combination of
midazolam/propofol might be a valuable alternative par-
ticularly for elderly patients with a high degree of co-
morbidity. We have therefore retrospectively analyzed
454 endoscopic procedures in 347 hospitalized patients
≥ 70 years who had received combined sedation with
midazolam/propofol; 513 procedures in 397 hospitalized
patients < 70 years who underwent endoscopic proce-
dures during the observation period served as controls.
Methods
We conducted a retrospective analysis of elective gastro-
intestinal endoscopies (esophago-gastro-duodenoscopy/
EGD; colonoscopy; endoscopic retrograde cholangio-
pancreaticography/ERCP; endoscopic ultrasound/EUS;
combined procedures: EGD with EUS or EGD with
colonoscopy) performed in hospitalized patients under
combined sedation with midazolam/propofol during an
8 months period (January-August 2006). Due to the ret-
rospective nature of the study, a formal approval of an
ethics committee has not to be obtained. Using a com-
puter-based search we identified 454 consecutive endo-
scopic procedures in 347 patients ≥ 70 years who had
received combined sedation with midazolam/propofol
(group A); 513 consecutive procedures in 397 hospita-
lized patients < 70 years who underwent endoscopy dur-
ing this time period served as controls (group B). Due to
the retrospective design of the study no formal approval
from an ethics committee was needed. According to the
standard protocol of our unit, sedation was initiated by
a second physician or a trained registered nurse with
midazolam 2.5 - 5 mg either as single agent or in com-
bination with fentanyl 0.05-0.1 mg. Propofol was added
as 10-20 mg bolus every 2 minutes until the desired
level of sedation - moderate to deep, according to the
procedure performed - was achieved. Monitoring was
carried out for oxygen saturation, heart rate and blood
pressure. All patients received nasal oxygen insufflations
at a rate of 2 L/min. Endoscopic procedures were car-
ried out by gastroenterologists with specific expertise in
gastrointestinal endoscopy with a second physician
experienced in intensive care on site. We recorded
patient age, gender, type of procedure, co-morbidity,
complications, procedure-related mortality and overall
28 day mortality.
Co-morbidity was classified as arterial hypertension,
diabetes mellitus, hyperlipoproteinemia, cardiovascular
disease (coronary or valvular heart disease, chronic con-
gestive heart failure), acute or chronic pulmonary dis-
ease (pneumonia, chronic obstructive pulmonary
disease) and chronic renal failure (serum creatinine >
1.2 mg/dl). In addition, patients periprocedural risk was
classified according to the American Association of
Anaestesiologists (ASA) classification [20]. Complica-
tions were categorized as respiratory (decrease in oxygen
saturation < 90% for > 120 sec), hemodynamic (decrease
in systolic blood pressure < 90 mmHg or decrease in
heart rate below 50/min for > 120 sec), agitation (neces-
sitating premature ending of the procedure). Complica-
tions were rated as severe if ventilatory or hemodynamic
support were needed or in case of procedure-associated
mortality from any cause.
Data are given as mean ± standard deviation. Statisti-
cal comparisons between the two groups of patients
were performed by Student’s t test for normally distribu-
ted data; proportions were analysed by Chi-Square or
Fisher’s exact test as appropriate. A two-sided error
level of p < 0.05 was considered statistically significant.
All statistics were computed with SPSS 15.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Characteristics of endoscopic procedures, medication,
outcome and complications were analysed and com-
pared for 454 procedures in 347 patients ≥ 70 years
(group A: mean age 78 ± 5 years) and 513 procedures
in 397 patients < 70 years old (group B: mean age 52 ±
14 years). There was a slight preponderance of male
patients in group B; the proportion of types of endo-
scopic procedures performed was similar in both groups
(table 1). Patients in group A had a significantly higher
level of co-morbidity than younger patients (p < 0.05;
table 2).
Sedation was initialized with midazolam or midazo-
lam/fentanyl and variable doses of propofol were added
to achieve the desired levels of sedation. Using this pro-
tocol with relatively fixed midazolam or midazolam/fen-
tanyl dosing and variable amounts of propofol as add-on
sedative, significantly lower amounts of propofol were
needed in the group of elderly patients (77.8 mg vs.
107.0 mg; p < 0.001; table 1; doses in table 1 are mean
± SD (range)). Minor complications were observed in a
total of 14 patients with no significant difference
between the groups (group A: 4 × respiratory complica-
tions, no hemodynamic complication and 1 × agitation;
group B: 1 × respiratory complication, 2 × hemody-
namic complications and 6 × agitation; table 1). All
patients who developed respiratory complications (n =
5) had significant co-morbidity and suffered from hyper-
tension and cardiovascular diseases; in addition, chronic
obstructive pulmonary disease was present in 2 of the
group A patients who developed respiratory complica-
tions. Hemodynamic complications were found in two
patients of the younger age group: one of them suffered
from severe co-morbidity (hypertension, cardiovascular
disease, diabetes, hyperlipidemia, chronic renal failure).
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cedure occurred more frequently, though not statistically
significant, in the younger age group (group B: n = 6 vs.
g r o u pA :n=1 ;p=N S ) .T h e r ew e r en os e v e r ee v e n t s
requiring assisted ventilation or hemodynamic support;
the procedure-associated mortality was 0%. There was
however a significant 28-day mortality which was signifi-
cantly higher in the elderly (group A: 2.9%/n = 13;
group B: 1.0%/n = 5; p = 0.03).
Discussion
It is well established that moderate sedation results in a
high level of both patient and physician satisfaction [1]
and may also improve the quality of upper GI endo-
scopy [5,6]. Data on combined sedation with midazo-
lam/propofol for gastrointestinal endoscopic procedures
in elderly patients are very rare. In this retrospective
analysis of midazolam/propofol sedation during 454
endoscopic procedures in 347 patients ≥ 70 years with
high-level co-morbidity reflected by a 28 day mortality
rate of 2.9% and an ASA score of class III or higher, we
have found no procedure-associated mortality or major
side effects. In comparison to patients of younger age,
elderly patients needed lower propofol doses (i.e.
showed a higher sensitivity to propofol) and but did not
have a significantly higher number of minor
complications.
While data on combined sedation with midazolam/
propofol for elderly patients are rare, our study has lim-
itations of a retrospective single-center study. Thus, a
patient selection bias cannot be excluded and data on
recovery times, quality of recovery or patient’s
satisfaction with sedation are lacking. Keeping these lim-
itations in mind, the safety data for propofol/midazolam
reported here are in line with data on the use of propo-
fol alone or in combination with meperidine in geriatric
patients with high-level of comorbidity. Thus, in a pro-
spective observational study on propofol sedation in 351
patients > 85 years, oxygen desaturation was more fre-
quent in the elderly and no major complication was
reported [10]. In another randomized prospective study,
propofol/meperidine sedation was compared to midazo-
lam/meperidine in 150 high risk octogenarians (91%
ASA class III or higher) with no significant increase in
complication rate but a better cooperation during ERCP
and decreased recovery times [11]. These data were con-
firmed in a recent study on 150 patients > 80 years
undergoing ERCP, endoscopic ultrasound or double bal-
lon enteroscopy who likewise did not experience major
complications although the rate of minor complications
was higher in patients receiving propofol [12]. The effect
of a combined sedation by adding propofol to midazo-
lam was investigated in 24 elderly patients with coronary
heart disease undergoing dentoalveolar surgery [21]. Sig-
nificantly lower systolic, diastolic and mean arterial pres-
sures were observed but all patients had stable
intraoperative hemodynamics and no major complica-
tion was reported.
While the data presented from this study, as well as
the data from other studies suggest a favorable safety
profile, the relatively small number of patients in these
studies must be considered. Indeed, severe complica-
tions of propofol sedation seem to be rare if pooled data
are analyzed from studies on patients with lower co-
Table 1 Patient characteristics
Group A (Age 70+) Group B (Age 18-69) p value
demographics
number of patients 347 (46.6%) 397 (53.4%) NS
age: Mean ± SD (years) 78 ± 5 52 ± 14 < 0.001
male 134 (38.6%) 212 (53.4%) < 0.001
female 213 (61.4%) 185 (46.6%) < 0.001
comorbidity
hypertension 292 (64.3%) 152 (29.6%) < 0.001
diabetes 113 (24.9%) 55 (10.7%) < 0.001
hyperlipidemia 125 (27.5%) 64 (12.5%) < 0.001
cardiovascular disease 277 (61.0%) 129 (25.1%) < 0.001
pulmonary disease 104 (22.9%) 83 (16.2%) 0.008
renal failure 127 (28.0%) 28 (5.5%) < 0.001
ASA class
I 3 (0.9%) 70 (17.6%) < 0.001
II 34 (9.8%) 105 (26.4%) < 0.001
III 263 (75.8%) 200 (50.4%) < 0.001
IV 47 (13.5%) 21 (5.3%) < 0.001
V 0 (0%) 1 (0.3%) NS
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major prospective studies, the complications rates of
endoscopist-administered propofol sedation were 3-7%
for transient hypoxia, 4-7% for transient hypotension
and only 0.1-0.2% for clinically important events requir-
ing assisted ventilation [22]. Thus, the limited number
of patients in this study, as well as in other published
studies might not have been sufficient to estimate the
true incidence of severe complications.
The other major finding of this retrospective analysis
is that significant lower propofol doses were needed for
elderly patients than for patients < 70 years (77.8 mg vs.
107.0 mg). While this difference might partially be due
to the higher level of comorbidity in the elderly, a dose
sparing synergistic effect of propofol/midazolam seda-
tion has been reported for the induction of anaesthesia
[23], from an observational study for patients under-
going gastrointestinal endoscopy [15] and randomized
controlled trials on propofol vs. propofol/midazolam
sedation for 239 patients undergoing upper GI endo-
scopy [16] and 200 outpatients undergoing colonoscopy,
respectively [18]. The data from this study point to an
Table 2 Endoscopic procedures, sedation and sedation-associated complications
Group A (Age 70+) Group B (Age 18-69) p value
total number of procedures 454(46.9%) 513(53.1%) NS
EGD 270(59.5%) 293(57.1%) NS
colonoscopy 92(20.3%) 115(22.4%) NS
ERCP 44(9.7%) 37(7.2%) NS
EUS 13(2.9%) 23(4.5%) NS
combined procedures 35(7.7%) 45(8.8%) NS
sedation, all procedures
midazolam 4.8 ± 3.3 (2.0-54.0) 4.9 ± 2.8 (2.0-65.0) NS
propofol 77.8 ± 70.1 (10-650) 107.0 ± 75.7 (20-500) < 0.001
fentanyl (n = 128 vs. 169 patients) 0.11 ± 0.11 (0.05-1.00) 0.12 ± 0.14 (0.05-1.00) NS
sedation, procedure-specific
EGD (n = 563)
- midazolam 4.5 ± 0.9 (2.0-10.0) 4.7 ± 0.6 (2.0-6.0) 0.021
- propofol 59.2 ± 35.6 (10-270) 97.5 ± 60.1 (20-500) < 0.001
- fentanyl (n = 7 vs. 4 patients) - - -
colonoscopy (n = 207)
- midazolam 4.6 ± 0.7 (3.0-5.0) 4.7 ± 0.5 (3.0-5.0) 0.045
- propofol 70.3 ± 58.7 (20-400) 75.4 ± 51.1 (30-420) NS
- fentanyl (n = 76 vs. 103 patients) 0.10 ± 0.01 (0.05-0.10) 0.13 ± 0.16 (0.05-1.00) NS
ERCP (n = 81)
- midazolam 5.0 ± 0.9 (3.0-10.0) 5.3 ± 1.2 (3.0-10.0) NS
- propofol 204.8 ± 121.3 (20-650) 202.2 ± 117.5 (40-450) NS
- fentanyl (n = 22 vs. 29 patients) 0.10 ± 0.0 (0.10-0.10) 0.09 ± 0.02 (0.05-0.10) NS
EUS (n = 36)
- midazolam 5.0 ± 0.0 (5.0-5.0) 4.9 ± 0.7 (3.0-7.0) NS
- propofol 70.0 ± 45.6 (10-150) 133.9 ± 83.4 (40-350) 0.016
- fentanyl (n = 9 vs. 1 patient) - - -
Group A (Age 70+) Group B (Age 18-69) p value
combined procedures (n = 80)
- midazolam 7.8 ± 11.2 (3.0-54.0) 6.4 ± 9.0 (3.0-65.0) NS
- propofol 84.3 ± 54.6 (30-300) 157.6 ± 86.4 (30-400) < 0.001
- fentanyl (n = 23 vs. 32 patients) 0.17 ± 0.26 (0.05-1.00) 0.13 ± 0.16 (0.05-1.00) NS
sedation-associated complications
- respiratory 4(0.9%) 1(0.2%) NS
- hemodynamic 0(0%) 2(0.4%) NS
- agitation 1(0.2%) 6(1.2%) NS
- procedure-associated mortality 0(0%) 0(0%) NS
- 28 day mortality 13(2.9%) 5(1.0%) 0.030
Kerker et al. BMC Gastroenterology 2010, 10:11
http://www.biomedcentral.com/1471-230X/10/11
Page 4 of 5increased sensitivity of the elderly population with
respect to the propofol dose to be used in combination
with midazolam. Further prospective data are needed to
support this finding.
Conclusions
In a retrospective comparative analysis of a geriatric
patient population with a high level of comorbidity, we
did not observe a significant increase in the complica-
tion rate for combined propofol/midazolam sedation for
gastrointestinal endoscopic procedures. However, the
sensitivity to propofol was found to be increased and
significantly lower propofol doses were needed for seda-
tion in this age group. These findings should be of inter-
est for gastroenterologists caring for elderly patients.
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